Counterfeit Medicine Circulating (Micardis Plus)

The manufacturer has issued a warning about the counterfeit and illegal sale of a batch of tablets, which pose a health risk.

On January 20, 2025, the Regulatory Agency for Health Control (Arcsa) issued an alert regarding the counterfeit batch of Micardis Plus 80/12.50mg tablets, lot number 104077. The product was falsified and unlawfully sold in Ecuador.

Boehringer Ingelheim, the company behind the product, notified Arcsa about the counterfeit version of their medication. Upon investigation, it was discovered that the batch, originally intended for the Turkish market, had been smuggled into Ecuador in fake packaging.

Health Risks

"Since this is a counterfeit product, we cannot guarantee its authenticity or its contents," warned Arcsa. "We have no traceability of its distribution or information on its supply chain. Therefore, we cannot ensure its quality, safety, or effectiveness."

As a result, this counterfeit medicine poses a significant health risk to the public.

Arcsa's Recommendations

- Do not sell, distribute, or use the Micardis® Plus 80/12.50mg tablets, lot 104077.

- Only purchase products with a valid Health Registration and from authorized establishments.

- If you encounter or have information about the illegal sale of this batch, report it to Arcsa via email at control.posterior@controlsanitario.gob.ec or through the Arcsa Mobile app.

- Report any adverse events related to the use of this medication to farmaco.vigilancia@controlsanitario.gob.ec.